Delivery of trefoil peptides

US7592013B2 · kind B2 · utility

Assignee

• ACTOGENIX N.V. · BE

Inventors

• Wolfgang Christian Hans · Landshut, DE
• Lothar Steidler · Lokeren, BE
• Erik Remaut · Vinderhoute, BE

Key dates

• Filing date: Jan 18, 2007
• Grant date: Sep 22, 2009
• Expiry date: Jan 18, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably the trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.